RU2016118573A - Анти-ly6e антитела и способы применения - Google Patents
Анти-ly6e антитела и способы применения Download PDFInfo
- Publication number
- RU2016118573A RU2016118573A RU2016118573A RU2016118573A RU2016118573A RU 2016118573 A RU2016118573 A RU 2016118573A RU 2016118573 A RU2016118573 A RU 2016118573A RU 2016118573 A RU2016118573 A RU 2016118573A RU 2016118573 A RU2016118573 A RU 2016118573A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- ly6e
- cancer
- seq
- sample
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 19
- 239000000523 sample Substances 0.000 claims 35
- 206010028980 Neoplasm Diseases 0.000 claims 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims 17
- 201000011510 cancer Diseases 0.000 claims 17
- 241000282414 Homo sapiens Species 0.000 claims 10
- 206010006187 Breast cancer Diseases 0.000 claims 6
- 208000026310 Breast neoplasm Diseases 0.000 claims 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 5
- 229940127121 immunoconjugate Drugs 0.000 claims 5
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 4
- 201000000498 stomach carcinoma Diseases 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000032383 Soft tissue cancer Diseases 0.000 claims 2
- 238000001574 biopsy Methods 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 101150029707 ERBB2 gene Proteins 0.000 claims 1
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108091008039 hormone receptors Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/534—Production of labelled immunochemicals with radioactive label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Optics & Photonics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (35)
1. Выделенное антитело, которое связывается с Ly6E, при этом антитело содержит (a) HVR-H3, содержащую аминокислотную последовательность SEQ ID NO:34, (b) HVR-L3, содержащую аминокислотную последовательность SEQ ID NO:31, и (c) HVR-H2, содержащую аминокислотную последовательность SEQ ID NO:33.
2. Антитело по п.1, при этом антитело содержит (a) HVR-H1, содержащую аминокислотную последовательность SEQ ID NO:32, (b) HVR-H2, содержащую аминокислотную последовательность SEQ ID NO:33, и (c) HVR-H3, содержащую аминокислотную последовательность SEQ ID NO:34.
3. Антитело по п.1 или 2, при этом антитело содержит (a) HVR-L1, содержащую аминокислотную последовательность SEQ ID NO:29; (b) HVR-L2, содержащую аминокислотную последовательность SEQ ID NO:30; и (c) HVR-L3, содержащую аминокислотную последовательность SEQ ID NO:31.
4. Антитело по пп. 1-3, содержащее (a) последовательность VH, имеющую по меньшей мере 95% идентичности последовательности с аминокислотной последовательностью SEQ ID NO:28; (b) последовательность VL, имеющую по меньшей мере 95% идентичности последовательности с аминокислотной последовательностью SEQ ID NO:27; или (c) последовательность VH как в (a) и последовательность VL как в (b).
5. Антитело по пп. 1-4, содержащее последовательность VH SEQ ID NO:28.
6. Антитело по пп. 1-5, содержащее последовательность VL SEQ ID NO:27.
7. Антитело, содержащее последовательность VH SEQ ID NO:28 и последовательность VL SEQ ID NO:27.
8. Антитело по пп. 1-7, которое является моноклональным антителом.
9. Антитело по п.8, которое является мышиным, кроличьим, человеческим, гуманизированным или химерным антителом.
10. Антитело по пп. 1-9, которое представляет собой IgG, выбранный из IgG1, IgG2a, IgG2b, IgG3 и IgG4.
11. Выделенная нуклеиновая кислота, кодирующая антитело по пп. 1-10.
12. Клетка-хозяина, содержащая нуклеиновую кислоту по п.11.
13. Способ получения антитела, включающий культивирование клетки-хозяина по п.13 таким образом, что антитело продуцируется.
14. Иммуноконъюгат, содержащий антитело по пп. 1-13 и цитотоксический агент.
15. Фармацевтический состав, содержащий иммуноконъюгат по п.14 и фармацевтически приемлемый носитель.
16. Антитело по пп. 1-10, конъюгированное с меткой.
17. Антитело по п.16, при этом метка представляет собой позитронный излучатель.
18. Антитело по п.17, при этом позитронный излучатель представляет собой 89Zr.
19. Способ детектирования человеческого Ly6E в биологическом образце, включающий приведение биологического образца в контакт с анти-Ly6E антителом по пп. 1-10 и 16-18 при условиях, позволяющих связывание анти-Ly6E антитела с встречающимся в природе человеческим Ly6E, и детектирование того, что комплекс образован между анти-Ly6E антителом и встречающимся в природе человеческим Ly6E в биологическом образце.
20. Способ по п.19, в котором анти-Ly6E антитело представляет собой антитело по п.7.
21. Способ по п.19, в котором биологический образец представляет собой образец рака молочной железы, образец рака поджелудочной железы, образец рака толстой кишки, образец колоректального рака, образец меланомного рака, образец рака яичника, образец немелкоклеточного рака легких, образец рака пищевода, образец рака головы и шеи, образец рака почки, образец рака мягких тканей, образец эндометриального рака или образец рака желудка.
22. Способ детектирования Ly6E-позитивного рака, включающий (i) введение меченого анти-Ly6E антитела объекту, имеющему или с подозрением на наличие Ly6E-позитивного рака, при этом меченое анти-Ly6E антитело содержит анти-Ly6E антитело по пп. 1-10, и (ii) детектирование меченого анти-Ly6E антитела у объекта, причем детектирование меченого анти-Ly6E антитела указывает на Ly6E-позитивный рак у объекта.
23. Способ по п.22, в котором меченое анти-Ly6E антитело представляет собой антитело по п.7, которое является меченым.
24. Способ по п.22 или 23, в котором меченое анти-Ly6E антитело содержит анти-Ly6E антитело, конъюгированное с позитронным излучателем.
25. Способ по п.24, в котором позитронный излучатель представляет собой 89Zr.
26. Способ идентифицирования ракового пациента как имеющего Ly6E-позитивный рак, включающий приведение в контакт образца рака от пациента с анти-Ly6E антителом по пп. 1-10 и 16-18 при условиях, позволяющих связывание анти-Ly6E антитела с встречающимся в природе человеческим Ly6E, и детектирование того, что комплекс образован между анти-Ly6E антителом и встречающимся в природе человеческим Ly6E в образце рака.
27. Способ по п.26, в котором раковый пациент идентифицирован как имеющий Ly6E-позитивный рак, если детектирован комплекс между анти-Ly6E антителом и встречающимся в природе человеческим Ly6E в биопсийном образце рака.
28. Способ выбора ракового пациента для лечения с иммуноконъюгатом, содержащим анти-Ly6E антитело, включающий приведение ракового образца от пациента в контакт с анти-Ly6E антителом по пп. 1-10 и 16-18 при условиях, позволяющих связывание анти-Ly6E антитела с встречающимся в природе человеческим Ly6E, и детектирование того, что комплекс образован между анти-Ly6E антителом и встречающимся в природе человеческим Ly6E в раковом образце.
29. Способ по п.28, в котором раковый пациент выбран, если детектирован комплекс между анти-Ly6E антителом и встречающимся в природе человеческим Ly6E в образце биопсии рака.
30. Способ по п.28 или 29, в котором иммуноконъюгат содержит анти-Ly6E антитело, содержащее (a) HVR-H1, содержащую аминокислотную последовательность SEQ ID NO:10, (b) HVR-H2, содержащую аминокислотную последовательность SEQ ID NO:11, (c) HVR-H3, содержащую аминокислотную последовательность SEQ ID NO:12, (d) HVR-L1, содержащую аминокислотную последовательность SEQ ID NO:7; (e) HVR-L2, содержащую аминокислотную последовательность SEQ ID NO:8; и (f) HVR-L3, содержащую аминокислотную последовательность SEQ ID NO:9.
31. Способ по п.30, в котором анти-Ly6E антитело содержит последовательность VH SEQ ID NO:5 и последовательность VL SEQ ID NO:3.
32. Способ по пп. 28-31, в котором иммуноконъюгат содержит анти-Ly6E антитело, конъюгированное с цитотоксическим агентом.
33. Способ по пп. 26-32, в котором раковый образец является образцом рака молочной железы, образцом панкреатического рака, образцом рака толстой кишки, образцом колоректалього рака, образцом меланомного рака, образцом рака яичников, образцом немелкоклеточного рака легких, образцом рака пищевода, образцом рака головы и шеи, образцом рака почки, образцом рака мягких тканей, образцом эндометриального рака или образцом рака желудка.
34. Способ по п.21 или 33, в котором образец рака молочной железы получен из Her2-позитивного рака молочной железы, Her2-негативного рака молочной железы, Her2-негативного/гормон рецептор позитивного (Her2-/ER+/PR+) рака молочной железы или трижды негативного (Her2-/ER-/PR-) рака молочной железы.
35. Способ по п.21 или 33, в котором образец рака желудка выбран из Her2-позитивного рака желудка или Her2-негативного рака желудка.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361893553P | 2013-10-21 | 2013-10-21 | |
US61/893,553 | 2013-10-21 | ||
PCT/US2014/061342 WO2015061209A1 (en) | 2013-10-21 | 2014-10-20 | ANTI-Ly6E ANTIBODIES AND METHODS OF USE |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2016118573A true RU2016118573A (ru) | 2017-11-28 |
RU2016118573A3 RU2016118573A3 (ru) | 2018-05-24 |
Family
ID=52993418
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2016118573A RU2016118573A (ru) | 2013-10-21 | 2014-10-20 | Анти-ly6e антитела и способы применения |
Country Status (15)
Country | Link |
---|---|
US (3) | US9290578B2 (ru) |
EP (1) | EP3060253B1 (ru) |
JP (1) | JP6707445B2 (ru) |
KR (1) | KR20160068963A (ru) |
CN (1) | CN105658237B (ru) |
AR (1) | AR098126A1 (ru) |
AU (1) | AU2014340378A1 (ru) |
BR (1) | BR112016008146A2 (ru) |
CA (1) | CA2924697A1 (ru) |
HK (1) | HK1225612A1 (ru) |
IL (1) | IL244643A0 (ru) |
MX (1) | MX2016004853A (ru) |
RU (1) | RU2016118573A (ru) |
SG (1) | SG11201603125SA (ru) |
WO (1) | WO2015061209A1 (ru) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112014028366A2 (pt) * | 2012-05-21 | 2017-06-27 | Genentech Inc | anticorpos anti-ly6e e imunoconjugados e métodos de uso |
AU2014340378A1 (en) * | 2013-10-21 | 2016-04-21 | Genentech, Inc. | Anti-Ly6E antibodies and methods of use |
JP6895254B2 (ja) | 2013-12-16 | 2021-06-30 | ジェネンテック, インコーポレイテッド | ペプチド模倣化合物及びその抗体−薬物コンジュゲート |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
EP3307780A1 (en) * | 2015-06-15 | 2018-04-18 | Genentech, Inc. | Antibodies and immunoconjugates |
ES2907486T3 (es) * | 2015-09-24 | 2022-04-25 | Univ North Carolina Chapel Hill | Métodos y composiciones para reducir metástasis |
CA3045466A1 (en) | 2016-12-01 | 2018-06-07 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
SG11201907208XA (en) | 2017-02-10 | 2019-09-27 | Regeneron Pharma | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
CA3070796A1 (en) | 2017-07-24 | 2019-01-31 | Regeneron Pharmaceuticals, Inc. | Anti-cd8 antibodies and uses thereof |
WO2021113648A1 (en) * | 2019-12-06 | 2021-06-10 | The University Of North Carolina At Chapel Hill | Affinity molecules that direct the metabolism and polarization of macrophages and synergize the immune checkpoint blockade therapy |
TW202406934A (zh) * | 2022-05-03 | 2024-02-16 | 美商建南德克公司 | 抗Ly6E抗體、免疫結合物及其用途 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US5773223A (en) | 1993-09-02 | 1998-06-30 | Chiron Corporation | Endothelin B1, (ETB1) receptor polypeptide and its encoding nucleic acid methods, and uses thereof |
US6913756B1 (en) | 1998-04-29 | 2005-07-05 | The Uab Research Foundation | Monoclonal antibodies specific for anthrax and peptides derived from the antibodies thereof |
US7387772B1 (en) | 1999-06-22 | 2008-06-17 | Immunimedics, Inc. | Chimeric, human and humanized anti-CSAP monoclonal antibodies |
EP2289549A3 (en) | 1999-10-01 | 2011-06-15 | Immunogen, Inc. | Immunoconjugates for treating cancer |
US7303749B1 (en) | 1999-10-01 | 2007-12-04 | Immunogen Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
US20050123925A1 (en) * | 2002-11-15 | 2005-06-09 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US20040185040A1 (en) | 2001-11-21 | 2004-09-23 | Celltech R & D Limited | Modulating immune responses |
WO2004010957A2 (en) | 2002-07-31 | 2004-02-05 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
AU2003259913A1 (en) * | 2002-08-19 | 2004-03-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
JPWO2005035754A1 (ja) | 2003-10-14 | 2006-12-21 | 中外製薬株式会社 | 機能蛋白質を代替する二種特異性抗体 |
BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
PL2311873T3 (pl) | 2004-01-07 | 2019-01-31 | Novartis Vaccines And Diagnostics, Inc. | Przeciwciało monoklonalne specyficzne wobec M-CSF i jego zastosowania |
EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
KR101200133B1 (ko) | 2004-06-01 | 2012-11-13 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
US20100111856A1 (en) * | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
CA2580141C (en) | 2004-09-23 | 2013-12-10 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
US20060094676A1 (en) | 2004-10-29 | 2006-05-04 | Ronit Lahav | Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity |
US20070134243A1 (en) | 2004-12-01 | 2007-06-14 | Gazzard Lewis J | Antibody drug conjugates and methods |
JP4993645B2 (ja) | 2004-12-01 | 2012-08-08 | ジェネンテック, インコーポレイテッド | 抗体薬剤結合体および方法 |
WO2007100385A2 (en) | 2005-10-31 | 2007-09-07 | Genentech, Inc. | Macrocyclic depsipeptide antibody-drug conjugates and methods |
CA2646597A1 (en) * | 2006-03-21 | 2007-09-27 | The Regents Of The University Of California | N-cadherin and ly6 e: targets for cancer diagnosis and therapy |
US20070269442A1 (en) | 2006-05-19 | 2007-11-22 | Robert J. Webber | Chimeric monoclonal antibody recognizing iNOS |
CN102159248B (zh) | 2008-07-15 | 2013-09-11 | 健泰科生物技术公司 | 蒽环类衍生物缀合物、它们的制备方法以及它们作为抗肿瘤化合物的用途 |
CA2752884A1 (en) | 2009-02-27 | 2010-09-02 | Genentech, Inc. | Methods and compositions for protein labelling |
GB0922434D0 (en) * | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | antibodies and fragments thereof |
AU2011221226A1 (en) | 2010-02-23 | 2012-08-16 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
CA2799540A1 (en) | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
JP5889912B2 (ja) | 2010-11-17 | 2016-03-22 | ジェネンテック, インコーポレイテッド | アラニニルメイタンシノール抗体コンジュゲート |
WO2012118813A2 (en) * | 2011-03-03 | 2012-09-07 | Apexigen, Inc. | Anti-il-6 receptor antibodies and methods of use |
BR112014028366A2 (pt) * | 2012-05-21 | 2017-06-27 | Genentech Inc | anticorpos anti-ly6e e imunoconjugados e métodos de uso |
AU2014340378A1 (en) * | 2013-10-21 | 2016-04-21 | Genentech, Inc. | Anti-Ly6E antibodies and methods of use |
US10077318B2 (en) * | 2014-09-12 | 2018-09-18 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
EP3307780A1 (en) * | 2015-06-15 | 2018-04-18 | Genentech, Inc. | Antibodies and immunoconjugates |
-
2014
- 2014-10-20 AU AU2014340378A patent/AU2014340378A1/en not_active Abandoned
- 2014-10-20 US US14/518,294 patent/US9290578B2/en active Active
- 2014-10-20 AR ARP140103935A patent/AR098126A1/es unknown
- 2014-10-20 KR KR1020167013092A patent/KR20160068963A/ko not_active Application Discontinuation
- 2014-10-20 SG SG11201603125SA patent/SG11201603125SA/en unknown
- 2014-10-20 BR BR112016008146A patent/BR112016008146A2/pt active Search and Examination
- 2014-10-20 EP EP14856653.2A patent/EP3060253B1/en active Active
- 2014-10-20 WO PCT/US2014/061342 patent/WO2015061209A1/en active Application Filing
- 2014-10-20 MX MX2016004853A patent/MX2016004853A/es unknown
- 2014-10-20 RU RU2016118573A patent/RU2016118573A/ru not_active Application Discontinuation
- 2014-10-20 CA CA2924697A patent/CA2924697A1/en not_active Abandoned
- 2014-10-20 CN CN201480055128.6A patent/CN105658237B/zh active Active
- 2014-10-20 JP JP2016525078A patent/JP6707445B2/ja active Active
-
2016
- 2016-02-08 US US15/018,710 patent/US10066022B2/en active Active
- 2016-03-17 IL IL244643A patent/IL244643A0/en unknown
- 2016-12-06 HK HK16113872A patent/HK1225612A1/zh unknown
-
2018
- 2018-07-31 US US16/050,936 patent/US10889651B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20170058042A1 (en) | 2017-03-02 |
AU2014340378A1 (en) | 2016-04-21 |
US9290578B2 (en) | 2016-03-22 |
SG11201603125SA (en) | 2016-05-30 |
EP3060253A1 (en) | 2016-08-31 |
KR20160068963A (ko) | 2016-06-15 |
AR098126A1 (es) | 2016-05-04 |
WO2015061209A1 (en) | 2015-04-30 |
CA2924697A1 (en) | 2015-04-30 |
JP2017500007A (ja) | 2017-01-05 |
CN105658237A (zh) | 2016-06-08 |
HK1225612A1 (zh) | 2017-09-15 |
RU2016118573A3 (ru) | 2018-05-24 |
IL244643A0 (en) | 2016-04-21 |
US10066022B2 (en) | 2018-09-04 |
MX2016004853A (es) | 2016-07-19 |
JP6707445B2 (ja) | 2020-06-10 |
BR112016008146A2 (pt) | 2017-10-03 |
EP3060253B1 (en) | 2018-12-19 |
EP3060253A4 (en) | 2017-05-17 |
US20150132218A1 (en) | 2015-05-14 |
CN105658237B (zh) | 2021-03-09 |
US20190085089A1 (en) | 2019-03-21 |
US10889651B2 (en) | 2021-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2016118573A (ru) | Анти-ly6e антитела и способы применения | |
CN110799539B (zh) | 抗4-1bb抗体及其制备和使用方法 | |
RU2430112C2 (ru) | Композиции и способы диагностики и лечения опухоли | |
RU2018119165A (ru) | Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение | |
HRP20180352T1 (hr) | Protutijela anti-fcrh5 | |
WO2015032906A4 (en) | Cd70-binding peptides and method, process and use relating thereto | |
JP2016523810A5 (ru) | ||
RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
RU2015142815A (ru) | Лечение рака с использованием антител, связывающихся с поверхностным grp78 | |
JP2018527919A5 (ru) | ||
JP2017149720A5 (ru) | ||
US20200347130A1 (en) | CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof | |
RU2017119543A (ru) | Анти-tim3 антитела и способы их применения | |
RU2017103495A (ru) | Антитела анти-pd-l1 и способы их диагностического применения | |
JP2017514461A5 (ru) | ||
JP2017534253A5 (ru) | ||
RU2016148616A (ru) | Анти-lgr5 антитела и их применение | |
JP2014534806A5 (ru) | ||
RU2016137110A (ru) | Антитела к компоненту комплемента с5 | |
JP2017522861A5 (ru) | ||
RU2014103784A (ru) | Антитело, блокирующее agr2, и его применение | |
JP2015506912A5 (ru) | ||
US10662250B2 (en) | Humanized monoclonal antibody specific to syndecan-1 | |
JP2012523848A5 (ru) | ||
RU2016114074A (ru) | Анти-rspo антитела и способы применения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180920 |